Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology
Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or/and EBUS, and MDT discussion concludes that immediate local surgery is not suitable
Have not received systematic anti-tumor treatment before
The researcher confirms at least one measurable lesion according to RECIST 1.1 criteria
Good lung function and able to tolerate surgical treatment
ECOG score is 0 to 1
You may not be if
Allergy to Sacituzumab Tirumotecan or any of its excipients
Patients allergic to Limertinib or any of its excipients
Patients with a history of other primary tumors; patients with a history of allogeneic organ transplantation
Major surgery within 4 weeks before the first dose (excluding diagnostic biopsy)
Patients with drug addiction such as drug abuse, long-term alcohol abuse, AIDS or HIV carriers
Patients with active or previously had and may recur autoimmune diseases
Currently receiving systemic hormone therapy (such as equivalent to more than 10 mg of prednisone per day or any other form of immunosuppressive therapy within 14 days before the first dose)
Patients who have received any EGFR-TKI or TROP2 ADC treatment before
Clareo Health | Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
